{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269486","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.190473+00:00","generated_at":"2026-05-16T23:28:19.995685+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"aTyr reports Q3 results; Phase 3 efzofitimod miss but plans FDA meeting","bullets":["Phase 3 EFZO-FIT missed primary endpoint of corticosteroid dose reduction at week 48; 5.0 mg/kg showed benefit on multiple quality-of-life measures.","Company plans FDA meeting in Q1 2026 to discuss path forward for efzofitimod in pulmonary sarcoidosis.","Phase 2 EFZO-CONNECT enrollment in SSc-ILD expected to complete H1 2026; interim data reported Q2 2025.","Cash, equivalents, restricted cash and investments $92.9M as of Sep 30, 2025.","R&D expenses $22.1M, G&A $4.8M for Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269486","json":"https://secwatch.observer/filing/0001193125-25-269486.json","markdown":"https://secwatch.observer/filing/0001193125-25-269486.md","text":"https://secwatch.observer/filing/0001193125-25-269486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000119312525269486/0001193125-25-269486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000119312525269486/atyr-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:28:19.995685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}